Compounds > adenine

adenine and bortezomib

adenine has been researched along with bortezomib in 41 studies

Research

Studies (41)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (2.44)29.6817
2010's33 (80.49)24.3611
2020's7 (17.07)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Benavides, A; Frost, P; Hoang, B; Lichtenstein, A; Shi, Y1
Belloni, D; Caligaris-Cappio, F; Dell'Antonio, G; Ferrarini, M; Ferrero, E; Foglieni, C; Veschini, L1
Sun, S; Tong, H; Tu, Y; Wang, G; Wei, W; Yao, F1
Ding, ZB; Fan, J; Gu, CY; Hui, B; Liu, WR; Peng, YF; Shi, GM; Shi, YH; Yang, H; Zhou, J1
Chowdhury, RD; Driscoll, JJ1
Barrera, LN; Bowles, KM; MacEwan, DJ; Murray, MY; Rushworth, SA; Zaitseva, L1
Dasmahapatra, G; Dent, P; Fisher, RI; Friedberg, J; Grant, S; Patel, H1
Feng, J; Leng, X; Li, J; Li, W; Lian, S; Wang, C; Wang, H; Zhang, X1
Chen, Y; Deng, Y; Deng, ZK; He, ZM; Li, YY; Tao, SD; Yu, L; Zhang, X1
Blum, KA; Maddocks, K1
Chen, ZR; Huang, M; Min, H; Xu, M; Zheng, K; Zhou, JD; Zou, XP1
Hu, C; Liu, J; Tian, Y; Tian, Z; Wang, C; Wang, X1
Guo, S; Li, Q; Qu, F; Wang, Y; Xia, B; Yang, H; Yuan, T; Zhang, Q; Zhang, Y; Zhao, W1
Auger, MJ; Bowles, KM; Craig, JI; MacEwan, DJ; Murray, MY; Rushworth, SA; Zaitseva, L1
Castillo, JJ; Ghobrial, IM; Treon, SP1
Bodo, J; Chen-Kiang, S; Di Liberto, M; Durkin, L; Elemento, O; Eng, K; Hsi, ED; Shetty, S; Smith, MR; Zhao, X1
Treon, SP1
Gong, J; Mita, M; Rimel, B; Sachdev, E1
Bader, J; Besse, L; de Bruin, G; Driessen, C; Geurink, PP; Kisselev, AF; Kraus, J; Kraus, M; Liu, N; Overkleeft, H1
Bayerl, S; Dreyling, M; Hiddemann, W; Hutter, G; Zimmermann, Y; Zoellner, AK1
Cheah, CY; Seymour, JF; Wang, ML1
Andersen, PM; Birve, A; Forsgren, E; Gilthorpe, JD; Keskin, I; Lange, DJ; Marklund, SL; Synofzik, M; Weber, M1
Ailawadhi, S; Akhtar, S; Ansell, SM; Bashir, Y; Caulfield, TR; Chanan-Khan, A; Chitta, K; Cogen, D; Coleman, M; Edenfield, B; Hudec, R; Jiang, J; Linder, S; Martin, P; Novak, A; Paulus, A; Paulus, SM; Roy, V; Samuel, K; Tran, D; Witzig, T; Yousaf, H1
Dimopoulos, MA; Kastritis, E1
Ailawadhi, S; Ansell, SM; Bergsagel, PL; Braggio, E; Buadi, FK; Chanan-Khan, A; Colgan, JP; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Go, RS; Gonsalves, WI; Greipp, PT; Grogan, M; Habermann, TM; Hayman, SR; Hwa, YL; Inwards, DJ; Jevremovic, D; Johnston, PB; Kapoor, P; Ketterling, RP; King, RL; Kumar, SK; Kyle, RA; Lacy, MQ; Leung, N; Lin, Y; Lust, JA; Markovic, SN; Mauermann, M; Micallef, IN; Mikhael, JR; Morice, WG; Novak, A; Nowakowski, GS; Porrata, LF; Rajkumar, SV; Reeder, CB; Roy, V; Russell, SJ; Sher, T; Stewart, AK; Thompson, CA; Witzig, TE; Zeldenrust, SR1
Augustson, B; Brown, R; Gibson, J; Grigoriadis, G; Harrison, S; Ho, JP; Horvath, N; Jaksic, W; Johnston, A; Joshua, D; Kalff, A; Kalro, A; Lee, C; Mollee, P; Prince, HM; Quach, H; Roberts, AW; Spencer, A; Szer, J; Talaulikar, D; Tam, CS; Trotman, J; Ward, C; Zannettino, A1
Chen, W; Lee, HJ; Nomie, K; Oriabure, O; Romaguera, J; Srour, SA; Wang, ML; Ye, H1
Lee, CM; Morgan, ET; Tripathi, S1
Bigenzahn, JW; Choi, HS; Felberbauer, F; Gisslinger, H; Gültekin, S; Hoermann, G; Jäger, U; Jeryczynski, G; Kazianka, L; Kenner, L; Korkmaz, B; Kornauth, C; Krall, N; Kralovics, R; Kubicek, S; Lopez de la Fuente, O; Mayerhoefer, ME; Merkel, O; Miura, K; Müllauer, L; Ocko, K; Prager, GW; Prutsch, N; Ringler, A; Sabler, M; Schmolke, AS; Simonitsch-Klupp, I; Snijder, B; Sperr, WR; Staber, PB; Superti-Furga, G; Valent, P; van der Kouwe, E; Vladimer, GI1
Till, BG1
Alijanazreh, H; Gentile, M; Hamamreh, Y; Hindiyeh, M; Kashkeesh, A; Morabito, F; Morabito, L; Recchia, AG; Sabatleen, A; Skafi, M1
Abhyankar, S; Kabadi, SM; Signorovitch, J; Song, J; Telford, C; Yao, Z; Zhao, J1
Anagnostopoulos, A; Briso, EM; Cascavilla, N; Dobkowska, E; García Sanz, R; Hajek, R; Hauns, B; Lee, Y; Martin Sánchez, J; Oriol, A; Ozcan, M; Pour, L; Špička, I; Terjung, A1
Ashelford, K; Corcoran, DB; Fegan, CD; Giles, PJ; Lewis, T; Miraz Rahman, K; Pepper, AGS; Pepper, C; Thurston, DE; Walsby, EJ1
Bonaldi, L; Branca, A; Gurrieri, C; Manni, S; Martines, A; Piazza, F; Pizzi, M; Riva, M; Scapinello, G; Semenzato, G; Trentin, L; Visentin, A1
Burningham, Z; Chien, HC; Halwani, AS; Li, CY; Morreall, D; Passey, DG; Patil, V; Rasmussen, KM; Sauer, BC; Yong, CM1
Castillo, JJ; Flynn, CA; LaMacchia, J; Pozdnyakova, O; Sarosiek, S; Treon, SP1
Bittner, A; Bogner, C; Bullinger, L; Denker, S; Dürig, J; Frick, M; Hoffmann, J; Hüttmann, A; Janz, M; Kase, J; Keller, U; Krohn, U; Marks, R; Mathas, S; Na, IK; Schmitt, CA; Trenker, C1
Amantini, C; Maggi, F; Marinelli, O; Morelli, MB; Santoni, G; Santoni, M1

Reviews

9 review(s) available for adenine and bortezomib

ArticleYear
Molecular crosstalk between the proteasome, aggresomes and autophagy: translational potential and clinical implications.
    Cancer letters, 2012, Dec-28, Volume: 325, Issue:2

    Topics: Adenine; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Chloroquine; Clinical Trials as Topic; Drug Resistance, Neoplasm; Drug Synergism; Forecasting; Humans; Inclusion Bodies; Medical Oncology; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; Translational Research, Biomedical; Ubiquitin

2012
Ibrutinib in B-cell Lymphomas.
    Current treatment options in oncology, 2014, Volume: 15, Issue:2

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Thalidomide; Treatment Outcome

2014
Biology, prognosis, and therapy of Waldenström Macroglobulinemia.
    Cancer treatment and research, 2015, Volume: 165

    Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Everolimus; Humans; Piperidines; Prognosis; Proteasome Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Salvage Therapy; Sirolimus; Stem Cell Transplantation; Waldenstrom Macroglobulinemia

2015
Mantle Cell Lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, Apr-10, Volume: 34, Issue:11

    Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Cytarabine; Drug Administration Schedule; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Molecular Targeted Therapy; Neoplasm Staging; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Risk Factors; Rituximab; Thalidomide; Transplantation, Autologous

2016
Current therapy guidelines for Waldenstrom's macroglobulinaemia.
    Best practice & research. Clinical haematology, 2016, Volume: 29, Issue:2

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Humans; Immunotherapy; Mutation; Myeloid Differentiation Factor 88; Piperidines; Practice Guidelines as Topic; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Waldenstrom Macroglobulinemia

2016
Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
    JAMA oncology, 2017, Sep-01, Volume: 3, Issue:9

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Cyclophosphamide; Dexamethasone; Everolimus; Humans; Myeloid Differentiation Factor 88; Piperidines; Plasma Exchange; Pyrazoles; Pyrimidines; Retreatment; Risk Assessment; Rituximab; Waldenstrom Macroglobulinemia

2017
Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma.
    Current treatment options in oncology, 2018, 07-21, Volume: 19, Issue:9

    Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Everolimus; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Prednisone; Pyrazoles; Pyrimidines; Rituximab; Vincristine; Young Adult

2018
Lenalidomide for the treatment of mantle cell lymphoma.
    Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:5

    Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Piperidines; Pyrazoles; Pyrimidines; Treatment Outcome

2019
Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
    Clinical therapeutics, 2019, Volume: 41, Issue:11

    Topics: Adenine; Antineoplastic Agents; Benzamides; Bortezomib; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Piperidines; Pyrazines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Treatment Outcome

2019

Trials

2 trial(s) available for adenine and bortezomib

ArticleYear
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
    The Lancet. Haematology, 2017, Volume: 4, Issue:12

    Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine; Disease-Free Survival; Female; Hematologic Neoplasms; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Microscopy, Fluorescence; Middle Aged; Odds Ratio; Pilot Projects; Piperidines; Positron Emission Tomography Computed Tomography; Pyrazoles; Pyrimidines; Remission Induction; ROC Curve; Young Adult

2017
A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
    European journal of haematology, 2020, Volume: 104, Issue:5

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Piperidines; Prognosis; Recurrence; Retreatment; Treatment Outcome

2020

Other Studies

30 other study(ies) available for adenine and bortezomib

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Effect of autophagy on multiple myeloma cell viability.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:7

    Topics: Adenine; Antifungal Agents; Antimalarials; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Boronic Acids; Bortezomib; Cell Proliferation; Chloroquine; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Immunoblotting; Membrane Proteins; Microscopy, Fluorescence; Multiple Myeloma; Pyrazines; RNA, Small Interfering; Sirolimus; Thapsigargin; Tumor Cells, Cultured

2009
Bortezomib induces autophagic death in proliferating human endothelial cells.
    Experimental cell research, 2010, Apr-01, Volume: 316, Issue:6

    Topics: Adenine; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Cell Proliferation; Cells, Cultured; Endothelial Cells; Fibroblast Growth Factors; Humans; Microtubule-Associated Proteins; Multiple Myeloma; Protease Inhibitors; Pyrazines; Reactive Oxygen Species

2010
An autophagy inhibitor enhances the inhibition of cell proliferation induced by a proteasome inhibitor in MCF-7 cells.
    Molecular medicine reports, 2012, Volume: 5, Issue:1

    Topics: Adenine; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Green Fluorescent Proteins; Humans; Microtubule-Associated Proteins; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Recombinant Fusion Proteins

2012
Proteasome inhibitor interacts synergistically with autophagy inhibitor to suppress proliferation and induce apoptosis in hepatocellular carcinoma.
    Cancer, 2012, Nov-15, Volume: 118, Issue:22

    Topics: Adenine; Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chloroquine; Cysteine Proteinase Inhibitors; Humans; Leupeptins; Membrane Proteins; Microtubule-Associated Proteins; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines

2012
BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB.
    Cellular signalling, 2013, Volume: 25, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amides; Antineoplastic Agents; Boronic Acids; Bortezomib; Caspases; Cell Survival; Humans; I-kappa B Proteins; Lenalidomide; Multiple Myeloma; NF-kappa B; NF-KappaB Inhibitor alpha; Nitriles; Phosphorylation; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; RNA, Messenger; Signal Transduction; Thalidomide; Tumor Cells, Cultured

2013
The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
    British journal of haematology, 2013, Volume: 161, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; DNA Damage; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Endoplasmic Reticulum Stress; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Mitochondria; NF-kappa B; Piperidines; Proteasome Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Pyrazoles; Pyrimidines; Reactive Oxygen Species; Tumor Cells, Cultured

2013
Inhibition of autophagy enhances apoptosis induced by proteasome inhibitor bortezomib in human glioblastoma U87 and U251 cells.
    Molecular and cellular biochemistry, 2014, Volume: 385, Issue:1-2

    Topics: Adenine; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 7; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Glioblastoma; Humans; Mitochondria; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering; Signal Transduction; Ubiquitin-Activating Enzymes

2014
[Effect of PCI-32765 and bortezomib on proliferation and apoptosis of B-cell tumor cell lines and its mechanisms].
    Zhongguo shi yan xue ye xue za zhi, 2013, Volume: 21, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Leukemic; Humans; Inhibitor of Apoptosis Proteins; NF-kappa B; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines

2013
Bortezomib induces protective autophagy through AMP-activated protein kinase activation in cultured pancreatic and colorectal cancer cells.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:1

    Topics: Adenine; AMP-Activated Protein Kinases; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Cell Survival; Cells, Cultured; Chloroquine; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Humans; Neoplasm Proteins; Pancreatic Neoplasms; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; RNA Interference; RNA, Small Interfering

2014
Autophagic-lysosomal inhibition compromises ubiquitin-proteasome system performance in a p62 dependent manner in cardiomyocytes.
    PloS one, 2014, Volume: 9, Issue:6

    Topics: Adenine; Animals; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Heat-Shock Proteins; Lysosomes; Mice; Mice, Transgenic; Myocytes, Cardiac; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; Rats; Sequestosome-1 Protein; Ubiquitin

2014
[Effect of PI3Kδ inhibitor CAL-101 on myeloma cell lines and preliminary study of synergistic effects with other new drugs].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2014, Volume: 35, Issue:10

    Topics: Adenine; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Humans; Multiple Myeloma; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazines; Pyrazoles; Pyrimidines; Quinazolinones

2014
Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma.
    Cell cycle (Georgetown, Tex.), 2015, Volume: 14, Issue:14

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Bortezomib; Cell Survival; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; MicroRNAs; Multiple Myeloma; Neoplasm Recurrence, Local; Piperidines; Proteasome Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Real-Time Polymerase Chain Reaction; RNA Interference; Signal Transduction; Transcription Factor RelA; Tumor Cells, Cultured

2015
CCMCL1: a new model of aggressive mantle cell lymphoma.
    Blood, 2015, Apr-23, Volume: 125, Issue:17

    Topics: Adenine; Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Lymphoma, Mantle-Cell; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Neoplasm Transplantation; Neoplasms, Experimental; Piperidines; Pyrazines; Pyrazoles; Pyrimidines; Rituximab; Tumor Cells, Cultured

2015
How I treat Waldenström macroglobulinemia.
    Blood, 2015, Aug-06, Volume: 126, Issue:6

    Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Cyclophosphamide; Everolimus; Gene Expression; Genetic Predisposition to Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin M; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Differentiation Factor 88; Nitrogen Mustard Compounds; Oligopeptides; Piperidines; Plasmapheresis; Pyrazines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Sirolimus; Transplantation, Autologous; Vidarabine; Waldenstrom Macroglobulinemia

2015
Adnectin-targeted inhibitors: rationale and results.
    Current oncology reports, 2015, Volume: 17, Issue:8

    Topics: Adenine; Angiogenesis Inhibitors; Antineoplastic Agents; Bortezomib; Clinical Trials as Topic; Drug Evaluation, Preclinical; Fibronectins; Humans; Lenalidomide; Molecular Targeted Therapy; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Pyrazoles; Pyrimidines; Thalidomide; Vascular Endothelial Growth Factor Receptor-2

2015
The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:2

    Topics: Adenine; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Humans; I-kappa B Proteins; Lymphoma, Mantle-Cell; Multiple Myeloma; Oligopeptides; Phosphorylation; Piperidines; Proteasome Inhibitors; Pyrazines; Pyrazoles; Pyrimidines

2015
Temsirolimus inhibits cell growth in combination with inhibitors of the B-cell receptor pathway.
    Leukemia & lymphoma, 2015, Volume: 56, Issue:12

    Topics: Adenine; Antineoplastic Agents; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Antagonism; Drug Synergism; Humans; Lymphoma, Large B-Cell, Diffuse; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Signal Transduction; Sirolimus

2015
Effects of Cellular Pathway Disturbances on Misfolded Superoxide Dismutase-1 in Fibroblasts Derived from ALS Patients.
    PloS one, 2016, Volume: 11, Issue:2

    Topics: Adenine; Age of Onset; Aging; Amyotrophic Lateral Sclerosis; Autophagy; Bortezomib; C9orf72 Protein; Case-Control Studies; Cells, Cultured; DNA Repeat Expansion; Electron Transport Complex I; Endoplasmic Reticulum Stress; Enzyme-Linked Immunosorbent Assay; Fibroblasts; Genotype; Humans; Mutation; Protease Inhibitors; Proteasome Endopeptidase Complex; Protein Aggregation, Pathological; Protein Folding; Proteins; Proteolysis; Rotenone; Solubility; Superoxide Dismutase; Superoxide Dismutase-1

2016
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
    Prescrire international, 2016, Volume: 25, Issue:170

    Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17; Cytarabine; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Thalidomide; Tumor Suppressor Protein p53; Vidarabine

2016
Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells.
    Blood cancer journal, 2016, 11-04, Volume: 6, Issue:11

    Topics: Adenine; Apoptosis; Azepines; Benzylidene Compounds; Bortezomib; Cell Line, Tumor; Cell Survival; Deubiquitinating Enzymes; Drug Resistance, Neoplasm; Humans; Piperidines; Pyrazoles; Pyrimidines; Signal Transduction; Ubiquitin Thiolesterase; Waldenstrom Macroglobulinemia

2016
Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
    Internal medicine journal, 2017, Volume: 47, Issue:1

    Topics: Adenine; Advisory Committees; Antineoplastic Agents; Australia; Bendamustine Hydrochloride; Bone Marrow; Bortezomib; Humans; Immunoglobulin M; Mutation; Myeloid Differentiation Factor 88; Piperidines; Plasma Cells; Practice Guidelines as Topic; Pyrazoles; Pyrimidines; Rituximab; Societies, Medical; Waldenstrom Macroglobulinemia

2017
Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma.
    British journal of haematology, 2018, Volume: 181, Issue:4

    Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Rituximab

2018
Nitric oxide-regulated proteolysis of human CYP2B6 via the ubiquitin-proteasome system.
    Free radical biology & medicine, 2017, Volume: 108

    Topics: Adenine; Animals; Bortezomib; Coumarins; Cytochrome P-450 CYP2B6; Down-Regulation; HeLa Cells; Hepatocytes; Humans; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Donors; Nitric Oxide Synthase Type II; Proteasome Endopeptidase Complex; Proteolysis; Rats; Ubiquitin; Ubiquitination

2017
Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit NF-κB activity and synergise with bortezomib and ibrutinib in hematological cancers.
    Haematologica, 2021, 04-01, Volume: 106, Issue:4

    Topics: Adenine; Animals; Apoptosis; Benzodiazepines; Bortezomib; Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Inbred NOD; Mice, SCID; NF-kappa B; Piperidines; Pyrroles; Tumor Microenvironment

2021
A case of "double hit" mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib.
    Annals of hematology, 2020, Volume: 99, Issue:11

    Topics: Abnormal Karyotype; Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Bortezomib; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 8; Cyclin D1; Cytarabine; Drug Resistance, Neoplasm; Fatal Outcome; Gene Duplication; Genes, myc; Humans; Lymphoma, Mantle-Cell; Male; Oncogene Proteins, Fusion; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Rituximab; Translocation, Genetic

2020
Real-world treatment patterns and outcomes in a national study of veterans with Waldenström macroglobulinemia, 2006-2019.
    American journal of hematology, 2021, 06-01, Volume: 96, Issue:6

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Chlorambucil; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Kaplan-Meier Estimate; Piperidines; Prednisone; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies; Rituximab; Treatment Outcome; Veterans; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia

2021
Plasmablastic lymphoma transformation in a patient with Waldenström macroglobulinemia treated with ibrutinib.
    British journal of haematology, 2021, Volume: 195, Issue:3

    Topics: Adenine; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bortezomib; Clonal Evolution; Cyclophosphamide; Disease Progression; Doxorubicin; Fatal Outcome; Female; Humans; Immunoglobulin kappa-Chains; Immunoglobulin M; Lymph Nodes; Myeloid Differentiation Factor 88; Neoplasm Proteins; Piperidines; Plasmablastic Lymphoma; Prednisone; Protein Kinase Inhibitors; Vincristine; Waldenstrom Macroglobulinemia

2021
Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signals.
    Leukemia & lymphoma, 2022, Volume: 63, Issue:1

    Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Piperidines; Prednisone; Rituximab; Vincristine

2022
The Mucolipin TRPML2 Channel Enhances the Sensitivity of Multiple Myeloma Cell Lines to Ibrutinib and/or Bortezomib Treatment.
    Biomolecules, 2022, 01-09, Volume: 12, Issue:1

    Topics: Adenine; Apoptosis; Bortezomib; Cell Line, Tumor; Cell Proliferation; Humans; Multiple Myeloma; Piperidines

2022